Ensysce Biosciences (ENSC) Projected to Post Earnings on Tuesday

Ensysce Biosciences (NASDAQ:ENSC) is expected to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.85) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 9:30 AM ET.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.23. Ensysce Biosciences had a negative net margin of 88.76% and a negative return on equity of 167.23%. The business had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.67 million. On average, analysts expect Ensysce Biosciences to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Ensysce Biosciences Stock Performance

Shares of NASDAQ:ENSC traded down $0.03 during trading hours on Tuesday, hitting $2.12. 18,765 shares of the company’s stock traded hands, compared to its average volume of 649,919. The company’s fifty day simple moving average is $2.23 and its two-hundred day simple moving average is $2.24. The company has a market cap of $6.30 million, a price-to-earnings ratio of -0.53 and a beta of 1.14. Ensysce Biosciences has a 52 week low of $1.62 and a 52 week high of $14.67.

Wall Street Analyst Weigh In

Several research firms have weighed in on ENSC. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised Ensysce Biosciences to a “hold” rating in a research report on Saturday, October 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.